Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
about
Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infectionsComparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial.Oritavancin for acute bacterial skin and skin structure infections.Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthraxIntracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenoEmergence and management of drug-resistant enterococcal infections.Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections.Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Oritavancin: a long-acting antibacterial lipoglycopeptide.Study of macrophage functions in murine J774 cells and human activated THP-1 cells exposed to oritavancin, a lipoglycopeptide with high cellular accumulation.Pharmacodynamic evaluation of the activity of antibiotics against hemin- and menadione-dependent small-colony variants of Staphylococcus aureus in models of extracellular (broth) and intracellular (THP-1 monocytes) infections.Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates.A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically.Telavancin: mechanisms of action, in vitro activity, and mechanisms of resistance.Oritavancin Pharmacokinetics and Bone Penetration in Rabbits.Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility.Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United StatesBaseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method.Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.Assessment of oritavancin serum protein binding across species.Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies.Impact of human serum albumin on oritavancin in vitro activity against enterococci.Quality control MIC ranges used for telavancin with application of a revised CLSI reference broth microdilution method.Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus.Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.Evaluation of Non-Tissue Culture- versus Tissue Culture-Treated Microplates for Oritavancin Susceptibility Testing.In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans.Surface-stress sensors for rapid and ultrasensitive detection of active free drugs in human serum.
P2860
Q26799701-0F8E6EA6-C936-4991-B28D-C17E23C3DA15Q35065786-0D3AFD9D-56AD-4D19-B36D-BD54EB4A72ACQ36086423-07CDFE66-328A-440D-BFD4-1014D9F50D05Q36870766-B9DBF2BC-0733-481B-B9EB-1D2410B911B2Q37144809-9AAA9F8E-01F2-42F9-9CD4-28BCCCFBCF04Q37291346-7453AEAC-DFB1-4924-948C-A5F661621FF9Q38347765-9922A2CF-9F90-41BF-A8BE-CF7BE122D57BQ38646905-55F65307-1399-41E4-A271-3AD3182CD7C4Q38830176-78030A66-5857-4485-ACB6-1008820BA9A7Q39031976-F95CD97C-8FBF-4E9E-8D17-CDCE063D1EA9Q39352419-9E7AF4D2-01F8-49B7-883D-6B560753210DQ40513210-1D7E57AE-7C41-46D1-84C0-8D7713FEF883Q40993969-E4A4CE12-C17C-4324-8F08-70ED15A5147EQ41028154-8866765B-C13D-44E7-A2FA-709C7A53BBEAQ41073732-BB335139-0036-455E-B96C-C5A492C5BA10Q41290708-FD0D587C-27D5-4E33-B954-3D2B10743E77Q41493636-453B8DD2-29F8-4CB0-9BBC-DBD9445636ECQ41561992-9A26C024-095E-4023-9B94-E00A8F084ACCQ41687426-3245A11B-7281-4689-BE02-CEC7DE3CC171Q41858019-D3010670-A8AB-418B-863B-956B1242A76FQ42076292-8C338CB3-DF2D-4E9E-A8B4-928A824AD811Q42111507-FA31F70D-CF4E-4151-8A39-4A34123ED4CDQ42530056-4C340557-13C6-41D4-BE28-85C729272434Q42797044-E33AD757-2E4F-402F-AFE5-D2DF8C77F7BFQ43121854-5096D9D8-DF71-4F92-8D0F-304E002BCC5FQ43125915-FAADC240-F7B6-4791-AFAE-B47090315562Q43169904-19ABCFF3-E094-4D00-AA8D-D50F661B2D45Q43189837-D8FBBB9E-1A9C-4F43-9711-7D0EBD1CC532Q43834023-4891E7E9-96F8-4E95-9502-6E711AE4CE33Q49789445-4CD34354-4710-483B-BEBA-63EE606AB3C0Q51760113-7A656DE4-56D9-4F9F-8ECF-A0282E9DBC22Q53064264-00F90AFA-6C4A-4FA0-92A8-73255BC3282B
P2860
Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Effect of polysorbate 80 on or ...... ns for susceptibility testing.
@en
Effect of polysorbate 80 on or ...... ns for susceptibility testing.
@nl
type
label
Effect of polysorbate 80 on or ...... ns for susceptibility testing.
@en
Effect of polysorbate 80 on or ...... ns for susceptibility testing.
@nl
prefLabel
Effect of polysorbate 80 on or ...... ns for susceptibility testing.
@en
Effect of polysorbate 80 on or ...... ns for susceptibility testing.
@nl
P2093
P2860
P356
P1476
Effect of polysorbate 80 on or ...... ns for susceptibility testing.
@en
P2093
Adam Belley
Daniel F Sahm
Deborah C Draghi
Francis F Arhin
Geoffrey A McKay
Gregory Moeck
Ingrid Sarmiento
Parveen Grover
Thomas R Parr
P2860
P304
P356
10.1128/AAC.01513-07
P407
P577
2008-02-25T00:00:00Z